SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

Tianjin ConjuStar Biologics

Status and phase: Not yet enrolling; Phase 2

Conditions: HR+ Breast Cancer; TNBC - Triple-Negative Breast Cancer

Treatments: Drug: SC-101

Study type: Interventional

Funder types: Industry

Identifiers

NCT07080619

SC-101-201

Details and patient eligibility

About

This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.

Full description

The study will include multiple cohorts: triple-negative breast cancer (TNBC), HR-positive HER2-negative breast cancer, and other solid tumors.

Participants will receive SC-101 at a dose of 7.5 mg/m² once weekly, with treatment cycles lasting 28 days. The study aims to assess tumor response and safety until disease progression or other reasons for treatment discontinuation.

Eligibility requires patients to have locally advanced or metastatic tumors that have either relapsed after standard treatment, are resistant to treatment, or are not amenable to standard treatment. NECTIN4 gene amplification must be confirmed via tumor tissue testing.

Imaging assessments will be conducted every 8 weeks to evaluate tumor response. Safety follow-up will be performed 30 days after the last dose, with additional survival follow-ups every 12 weeks thereafter.

Enrollment: 120 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Age between 18 and 75 years (inclusive), regardless of gender.

ECOG performance status of 0-1.

Expected survival of more than 3 months, as assessed by the investigator.

Fertile participants must agree to use contraception.

Able to understand the trial requirements and willing and able to comply with the trial and follow-up procedures.

Adequate bone marrow and organ function.

NECTIN-4 gene amplification positive.

Exclusion criteria

Unstable central nervous system tumors.

Adverse reactions from previous anticancer treatments have not recovered to a CTCAE 5.0 grade ≤1.

A history of severe cardiovascular or cerebrovascular disease.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

120 participants in 1 patient group

TNBC, HR+HER2- BC, and other tumors

Experimental group

Description:

Receive 7.5 mg/m² of SC-101 intravenously once weekly (QW).

Treatment:

Drug: SC-101